Survivin in Medical News

Isis Highlights New Clinical Data on Anti-Cancer Antisense Drugs Featured at ASCO

...esented new data from a Phase 1 study of LY2181308 in patients with cancer. The new data confirmed that LY2181308 penetrates tumor tissue and reduces survivin mRNA and protein levels in tumor cells. In addition, Dr. Azeem Saleem, CRUK Senior Clinical Research Fellow, University of Manchester, presented resu...

New findings may improve treatment of inherited breast cancer

...cer initiation or progression has been identified. survivin is an apoptosis inhibitor that is dramatically ele... many types of tumors. Research has suggested that survivin may serve to maintain the tumor and promote growth...ntaining SIRT1 expression, which in turn inhibited survivin expression. When BRCA1 was not functioning properl...

Turned-off cannabinoid receptor turns on colorectal tumor growth

...that CB1 increases cancer cell death by stifling a protein called survivin. survivin is overexpressed in nearly every human tumor but is barely detectable in normal tissue, DuBois noted. Overexpression of survivin is associated with poor outcome and reduced apoptosis in colorectal cancer ...

Isis Reports Financial Results and Highlights for First Quarter of 2008

...se drug to enter clinical development for the treatment of asthma. o Lilly has advanced an antisense drug, LY2181308, which targets survivin for the treatment of cancer, into Phase 2 trials. -- Ibis Biosciences o Ibis, Isis' majority-owned subsidiary, has developed and is com...

Isis Reports Financial Results and Highlights for Fiscal year 2007

... OGX-427 that targets Hsp27 for cancer treatment. * Lilly expects to begin Phase 2 clinical studies of LY2181308 that targets survivin for cancer treatment. * The broad therapeutic potential of antisense drugs enables Isis to discover drugs that are outside of Isis' core focus...

Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy

...ancer and melanoma, with new Phase II studies now initiated for ovarian cancer and soft-tissue sarcoma. Phase II trials are set to begin for survivin ASO, an antisense molecule targeted at solid tumors that Lilly is developing with its partner, ISIS Pharmaceuticals; a second antisense mole...

A new chemotherapeutic target for hepatocellular carcinoma

... of HCC. The immunohistochemical expression of survivin in liver tumor specimens obtained from 17 patients was studied. In addition, to determine the survivin expression in response to anti-cancer drugs in early stage HCC, the survivin expression was determined after treating HCC cells...